ASX-listed Australian company LTR Pharma has announced a strategic partnership with wholesaler Symbion to facilitate the nationwide distribution of the novel nasal spray treatment for Erectile Dysfunction, SPONTAN.
LTR said the non-exclusive agreement, which begins on 1 March, means the company will work with Symbion to access its network of over 3,900 pharmacies nationwide.
Symbion's network includes warehousing, inventory functions, and distribution services.
LTR said Symbion will support its inventory management systems and integration, quality control and TGA-compliant product handling protocols, storage facility setups and maintenance, and the development of pharmacist education.
LTR said, "This collaboration will play a vital role in supporting the early access scheme that LTR will use and sets a new foundation for SPONTAN’s commercial launch following the appropriate regulatory approval process completion."
LTR Pharma chair Lee Rodne said, "Partnering with Symbion is a pivotal step in building our commercial infrastructure. Symbion’s extensive distribution network and expertise will ensure seamless access to SPONTAN across Australia. This agreement underscores our commitment to collaboration with industry leaders to establish a reliable supply chain, support the TGA’s early access program, and prepare for SPONTAN’s anticipated commercial launch. Together, we are ensuring the highest standards of pharmaceutical handling and service delivery.”